Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.
about
A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopesHigh affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticityStructural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF bindingVariants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding siteStructural Insights into the Binding of Vascular Endothelial Growth Factor-B by VEGFR-1D2: RECOGNITION AND SPECIFICITYStructure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic siteRationalization and Design of the Complementarity Determining Region Sequences in an Antibody-Antigen Recognition InterfaceMonovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agentA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsProbing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation studyAntiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection.Synthetic antibodies as therapeutics.Engineering anti-vascular endothelial growth factor single chain disulfide-stabilized antibody variable fragments (sc-dsFv) with phage-displayed sc-dsFv libraries.Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging studyClinical applications of a peptide-based vaccine for glioblastoma.Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbitsVEGF signaling mediates bladder neuroplasticity and inflammation in response to BCGMultiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes.Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in miceAffinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor.Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization.Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure.Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesProduction of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF.Functional analysis and transcriptional output of the Göttingen minipig genome.Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display systemTying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines.Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.Anti-Human VEGF Repebody Effectively Suppresses Choroidal Neovascularization and Vascular LeakagePeptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyAnti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation.Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning.Antigen clasping by two antigen-binding sites of an exceptionally specific antibody for histone methylationNovel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept.Hyperpolarized (13)C-lactate to (13)C-bicarbonate ratio as a biomarker for monitoring the acute response of anti-vascular endothelial growth factor (anti-VEGF) treatment.Corneal neovascularization during experimental fungal keratitis.Protein kinase inhibitors: contributions from structure to clinical compounds.
P2860
Q26860116-CD36868D-AD4C-474F-AABE-1180910158FEQ27349722-BD872AC7-4053-440B-AF9B-927FACC8D567Q27648978-AB9610FE-3285-4899-8318-7701EFFBD7B3Q27654214-CEC69680-E5B1-48FE-AC47-3178EE4D5745Q27661923-F564A190-7E68-4D86-9BD8-6B3AE81BA3F8Q27677823-8D91F075-2F85-4D95-9ED7-766E1599E097Q27678251-68D03CE7-149B-4ABE-8404-8C9E5D33EDFBQ27679191-80052E95-1575-47BB-8D62-E0DC7825F6A6Q28749085-4BCDDA7D-CA8A-4F76-A073-46ACEA8D02C7Q30155518-3774EE91-A643-4FB8-95C9-03795BB113E3Q30474689-1DFC8118-12C6-4B33-AFF6-058DBFB5822FQ33257951-3E468497-CDC8-4803-9298-695A54F55510Q33265617-F6BA9C4D-7FDB-4158-91E2-7AE0E2AEAAE5Q33523427-56FBE343-C256-4151-815B-A8BC1F00871CQ33591382-BCF0EE95-77F3-4DC5-9E27-FE3F9B75511CQ33655366-4657F636-897C-4BCA-A1AC-E33B72284D15Q33668575-18F81B54-E2FE-4F40-A33C-63B401328B59Q33911625-98751D0D-CF30-45DC-9F8F-7C0D524B0CFBQ34068680-DF07B327-D385-468D-8EE4-20B4FBD1AE1BQ34438836-C501CDAC-780A-4C38-88DC-F8E4714ED0C2Q34633674-7B99571F-F044-4CDE-B589-8934565DB35DQ34736631-961E63A7-2934-46E0-93FB-31510907197CQ34787415-B6E7B25B-22F4-4206-999E-28DF790216DBQ35103846-657A0910-CA21-4C5A-96DE-1958446A130CQ35213093-A141C13E-4D74-443C-9EA2-46D172BF60F2Q35652113-57734D70-F302-4938-A41C-0BEFDEFFEFCDQ35657061-EB1A4698-7447-41E3-8835-E1062D9CCA75Q35843080-1ECF4EDF-1334-4151-B9D4-5973EBAF181AQ35859635-90B97D40-659D-4D53-A990-94C71844C753Q35895234-73B87B28-3E23-4516-8CFB-32016ADC4CDCQ35918945-DB8D80F4-71EC-4A48-9A34-CAAE30BEE535Q35970500-8225722C-BE67-4D7C-B251-DBF3C186D18BQ36116250-004D7AFB-3C1D-4CEA-9908-CB019DCE435FQ36237474-433BC933-4E38-4302-9339-C8162A174E3DQ36393842-0A8B8FE1-BD3B-4F27-8E5B-69E46141DC3AQ36646360-50F0EF98-46DC-49E1-9B21-A98372A4CA2AQ36674580-7D6ECAA4-676E-4441-90D4-9B38310C6D54Q36803260-D936956E-8828-41B0-9186-2B9AFFDDEA86Q37373833-1C7624B5-C329-4DF3-B71E-BF27DBB56F89Q37417742-2C6F8BDB-A9E7-43D8-BF87-13C17DC06ED8
P2860
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Structure-function studies of ...... mparison with the Avastin Fab.
@ast
Structure-function studies of ...... mparison with the Avastin Fab.
@en
type
label
Structure-function studies of ...... mparison with the Avastin Fab.
@ast
Structure-function studies of ...... mparison with the Avastin Fab.
@en
prefLabel
Structure-function studies of ...... mparison with the Avastin Fab.
@ast
Structure-function studies of ...... mparison with the Avastin Fab.
@en
P2093
P2860
P356
P1476
Structure-function studies of ...... omparison with the Avastin Fab
@en
P2093
Barbara Moffat
Chingwei V Lee
Germaine Fuh
Mark Ultsch
Wei-Ching Liang
P2860
P304
P356
10.1074/JBC.M507783200
P407
P577
2005-12-22T00:00:00Z